UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 1-35447 APTOSE BIOSCIENCES INC. (Exact Name of Registrant as Specified in Its Charter) Canada (State or other jurisdiction of incorporatio ...

Aptose Biosciences Inc. (NASDAQ:APTO) Q2 2020 Earnings Conference Call August 4, 2020 5:00 PM ET Company Participants Susan Pietropaolo - SMP Communications William Rice - Chairman, President & CEO Gregory Chow - EVP & CFO Rafael Bejar - SVP & CMO Jotin Marango - SVP & CBO Conference Call Participants Tyler Van Buren - Piper Sandler Gregory Renza - RBC Capital Markets John Newman - Canaccord Matt Biegler - Oppenheimer Naureen Quibria - Maxim Group Operator Good afternoon. My name is Victor, and I will be yo ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 1-35447 APTOSE BIOSCIENCES INC. (Exact Name of Registrant as Specified in Its Charter) Canada (State or other jurisdiction of incorporation or ...

Aptose Biosciences Inc. (NASDAQ:APTO) Q1 2020 Earnings Conference Call May 5, 2020 5:00 PM ET Company Participants Susan Pietropaolo - SMP Communications William Rice - Chairman, President and CEO Gregory Chow - EVP and CFO Rafael Bejar - SVP and CMO Jotin Marango - SVP and CBO Conference Call Participants Tyler Van Buren - Piper Sandler John Newman - Canaccord Gregory Renza - RBC Capital Markets Matt Biegler - Oppenheimer Naureen Quibria - Maxim Group Matthew Cross - JonesTrading Operator Good afternoon. M ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 1-35447 APTOSE BIOSCIENCES INC. (Exact Name of Registrant as Specified in Its Charter) Canada (State or other jurisdiction of incorporation or ...

Aptose Biosciences Inc. (NASDAQ:APTO) Q4 2019 Earnings Conference Call March 10, 2020 5:00 PM ET Company Participants Susan Pietropaolo - SMP Communications William Rice - Chairman, President & Chief Executive Officer Gregory Chow - Executive Vice President & Chief Financial Officer Jotin Marango - Senior Vice President & Chief Business Officer Rafael Bejar - Senior Vice President & Chief Medical Officer Conference Call Participants Tyler Van Buren - Piper Sandler Gregory Renza - RBC Capital John Newman - ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark one) ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019. ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-3200 APTOSE BIOSCIENCES INC. (Exact name of registrant as specified in its charter) Canada (State or other jurisdiction of incorporation or organization) 98-1136802 (I.R.S. Employer ...